Cytek Biosciences (CTKB) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 7% year-over-year to $51.5 million, driven by strong growth in EMEA and APAC, robust service revenue, and an expanding installed base of 2,821 instruments.

• Net income for Q3 2024 was $0.9 million, reversing a net loss of $6.5 million in Q3 2023, supported by improved operating results, foreign exchange gains, and a tax benefit.

• Continued investment in R&D and product innovation, including the launch of the Spectral Panel tool and enhancements to the digital ecosystem.

• Completed the acquisition of FlowCEL assets in October 2024 and continued integration of Amnis and Guava instruments from the Luminex acquisition.

• Expanded Cytek Cloud user base to over 13,600, more than doubling since the start of the year.

Financial highlights

• Q3 2024 revenue was $51.5M (+7% YoY, +10% sequentially); YTD revenue at $143.0M (+6% YoY).

• Product revenue was $39.5M (+3% YoY in Q3), service revenue $12.0M (+25% YoY in Q3, +41% YTD).

• GAAP gross profit was $29.0M (56% margin), adjusted gross margin 60%; operating expenses were $33.3M, down 1% YoY.

• Adjusted EBITDA reached $7.6M, up from $3.7M in Q3 2023.

• Cash and marketable securities totaled $277.8M as of September 30, 2024, despite $12.1M in share repurchases.

Outlook and guidance

• 2024 revenue guidance reaffirmed at $203M–$210M, representing 5%–9% growth over 2023.

• Expects a net loss in the single-digit millions for full year 2024, with a goal of positive net income going forward.

• Anticipates continued positive cash flow from operations and normal seasonal patterns in Q4, with strongest growth in EMEA and APAC.

• Management expects expenses to remain relatively flat and will focus on new product development and revenue growth.

• Existing cash and anticipated cash flows are expected to meet working capital and capital expenditure needs for at least the next 12 months.